89bio to Present at Upcoming Investor Conferences

Rhea-AI Summary

89bio, a clinical-stage biopharmaceutical company (Nasdaq: ETNB), announced CEO Rohan Palekar's participation in two upcoming conferences. He will speak at the BTIG Virtual Biotechnology Conference on August 10, 2020, at 11:30 AM ET, and at the Canaccord Genuity 40th Annual Growth Conference on August 12, 2020, at 10:00 AM ET. The company is developing therapies for liver and cardio-metabolic diseases, including its lead candidate, BIO89-100, targeted for NASH treatment. Webcasts will be available on their website after the events.

SAN FRANCISCO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the company’s Chief Executive Officer, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference 2020 on Monday, August 10 , 2020 at 11:30 AM ET and the Canaccord Genuity 40^th Annual Growth Conference on Wednesday, August 12, 2020 at 10:00 AM ET.

The live and archived webcast of the presentation will be accessible from the company’s website at https://ir.89bio.com/events-and-presentations. The replay of the webcast will be available on the company’s website.

About 89bio

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is being developed for the treatment of NASH and for the treatment of SHTG. BIO89-100 is a specifically engineered glycoPEGylated analog of FGF21 that is currently in a proof of concept Phase 1b/2a clinical trial in patients with NASH or NAFLD and a high risk of NASH. 89bio is headquartered in San Francisco with operations in Herzliya, Israel. Visit 89bio.com for more information.

Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com

Media Contact:
Lori Rosen
LDR Communications
917-553-6808
lori@ldrcommunications.com

FAQ

When will 89bio's CEO speak at the BTIG Virtual Biotechnology Conference?

Rohan Palekar will speak on August 10, 2020, at 11:30 AM ET.

What is the focus of 89bio's development?

89bio focuses on therapies for liver and cardio-metabolic diseases.

What is BIO89-100?

BIO89-100 is 89bio's lead product candidate for treating NASH.

When is the Canaccord Genuity 40th Annual Growth Conference?

The conference is on August 12, 2020, at 10:00 AM ET.

Where can I access the webcast of the presentations?

The webcast can be accessed on 89bio's website after the presentations.